SCHEMBL4116012

SCHEMBL4116012

CCc1cc(C(=O)O)c(C(=O)O)cc1CC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 3/20 0.50
GABRD O14764 3/20 0.50
GABRA1 P14867 3/20 0.50
GABRB1 P18505 3/20 0.50
GABRG2 P18507 3/20 0.50
GABRB3 P28472 3/20 0.50
GABRA5 P31644 3/20 0.50
GABRA3 P34903 3/20 0.50
GABRA2 P47869 3/20 0.50
GABRB2 P47870 3/20 0.50
GABRA4 P48169 3/20 0.50
GABRE P78334 3/20 0.50
GABRA6 Q16445 3/20 0.50
GABRG1 Q8N1C3 3/20 0.50
GABRG3 Q99928 3/20 0.50
GABRQ Q9UN88 3/20 0.50
CLCN2 P51788 2/20 0.46
ALDH1A1 P00352 5/20 0.41
HSD17B10 Q99714 2/20 0.41
HMGB1 P09429 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2334997 0.89 GABRP (0.55) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL5154636 0.87 GABRP (0.46) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL3526804 0.85 ALOX15 (0.47) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL19873252 0.84 HSD17B10 (0.56) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL29077089 0.84 HSD17B10 (0.47) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL11550272 0.84 GABRP (0.52) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL4640738 0.84 ALDH1A1 (0.47) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL15375739 0.80 HMGB1 (0.48) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL23879428 0.80 FABP3 (0.42) GABRPGABRDGABRA1GABRB1GABRG2
Pyromellitic Acid SCHEMBL15005172 0.80 GABRP (0.42) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-3120266-A None JP disclosed
CN-110997795-B High stiffness polypropylene impact copolymers 埃克森美孚化学专利公司 2022-10-04 CN disclosed
CN-103764690-B Process for producing solid catalyst component for olefin polymerization, catalyst for olefin polymerization, and process for producing olefin polymer 东邦钛株式会社 2016-12-14 CN disclosed
CN-103189396-B The manufacture method of solid catalyst component for olefin polymerization, polymerization of olefines catalyst and olefin polymer 东邦钛株式会社 2016-06-29 CN disclosed
CN-102159596-B Solid catalyst component and catalyst for polymerization of olefins, and process for production of olefin polymers using same TOHO TITANIUM CO LTD 2014-05-07 CN disclosed
CN-103764690-A Process for producing solid catalyst component for olefin polymerization, catalyst for olefin polymerization, and process for producing olefin polymer TOHO TITANIUM CO LTD 2014-04-30 CN disclosed
CN-103189396-A Method for producing solid catalyst component for olefin polymerization, catalyst for olefin polymerization, and olefin polymers TOHO TITANIUM CO LTD 2013-07-03 CN disclosed
CN-103087222-A Olefin polymerization catalyst, process for producing olefin polymer, polypropylene resin composition and article comprising the same SUMITOMO CHEMICAL CO 2013-05-08 CN disclosed
EP-1566378-B1 ISOINDOLINE DERIVATIVE MARUISHI PHARMA (JP) 2012-08-15 EP disclosed
CN-102159596-A Solid catalyst component and catalyst for polymerization of olefins, and process for production of olefin polymers using same TOHO TITANIUM CO LTD 2011-08-17 CN disclosed
US-7521451-B2 Isoindoline derivative MARUISHI PHARMACEUTICAL CO., LTD. (JP) 2009-04-21 US disclosed
US-20080021042-A1 Composition For Controlling Neuropathic Pain MARUISHI PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 US disclosed
US-20080021042-A1 Composition For Controlling Neuropathic Pain MARUISHI PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 US disclosed
US-20080021042-A1 Composition For Controlling Neuropathic Pain MARUISHI PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 US disclosed
CN-1956955-A Neuropathic pain controlling agent composition MARUISHI PHARMA (JP) 2007-05-02 CN disclosed
EP-1749817-A1 NEUROGENIC PAIN CONTROL AGENT COMPOSITION Maruishi Pharmaceutical Co., Ltd. (JP) 2007-02-07 EP disclosed
US-20060052392-A1 e.g. 5,6-dimethyl-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione;intravenous, water-soluble compounds useful for manufacturing an anasthetic, sedative agents; side effect reduction MARUISHI PHARMACEUTICAL CO., LTD 2006-03-09 US disclosed
CN-1741995-A Isoindoline derivative MARUISHI PHARMA (JP) 2006-03-01 CN disclosed
EP-1566378-A1 ISOINDOLINE DERIVATIVE Maruishi Pharmaceutical Co., Ltd. (JP) 2005-08-24 EP disclosed
JP-H03120266-A 4,5-DIETHYL PHTHALATE AND DERIVATIVE THEREOF NIPPON STEEL CHEM CO LTD 1991-05-22 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052392-A1 e.g. 5,6-dimethyl-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione;intravenous, water-soluble compounds useful for manufacturing an anasthetic, sedative agents; side effect reduction CYP3A5, OPRD1, CYP3A7 GABRP 131/4885GABRD 42/4885GABRA1 144/4885
US-20080021042-A1 Composition For Controlling Neuropathic Pain GAP43, SCN10A, SCN2A GABRP 170/4885GABRD 341/4885GABRA1 371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.